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Psoralen andultravioletA light (PUVA) are used to kill patho-
gens in blood products and as a treatment of aberrant cell pro-
liferation in dermatitis, cutaneous T-cell lymphoma, and graft-
versus-host disease. DNA damage is well described, but the
direct effects of PUVA on cell signal transduction are poorly
understood. Because platelets are anucleate and contain arche-
typal signal transduction machinery, they are ideally suited to
address this. Lipidomics on platelet membrane extracts showed
that psoralen forms adducts with unsaturated carbon bonds of
fatty acyls in all major phospholipid classes after PUVA. Such
adducts increased lipid packing asmeasured by a blue shift of an
environment-sensitive fluorescent probe in model liposomes.
Furthermore, the interaction of these liposomes with lipid
order-sensitive proteins like amphipathic lipid-packing sensor
and -synuclein was inhibited by PUVA. In platelets, PUVA
caused poor membrane binding of Akt and Bruton’s tyrosine
kinase effectors following activation of the collagen glycopro-
tein VI and thrombin protease-activated receptor (PAR) 1. This
resulted in defective Akt phosphorylation despite unaltered
phosphatidylinositol 3,4,5-trisphosphate levels. Downstream
integrin activation was furthermore affected similarly by PUVA
following PAR1 (effective half-maximal concentration (EC50),
8.4 1.1 versus 4.3 1.1M) and glycoprotein VI (EC50, 1.61
0.85 versus0.260.21g/ml) butnotPAR4 (EC50, 501 versus
58 1M) signal transduction. Our findings were confirmed in
T-cells from graft-versus-host disease patients treated with
extracorporeal photopheresis, a formof systemic PUVA. In con-
clusion, PUVA increases the order of lipid phases by covalent
modification of phospholipids, thereby inhibiting membrane
recruitment of effector kinases.
Psoralens are linear furanocoumarins. Their heterocyclic
aromatic core reversibly intercalates in nucleic acid clefts of cell
nuclei (1). Absorption of ultraviolet A (UVA)2 light excites the
psoralen, supplying energy for covalent bond formation.When
in the vicinity of nucleic acids, the reaction is primarily with
pyrimidine moieties (2). This chemical addition is irreversible
and prevents normal replication of DNA (3), explaining why
severe phytophotodermatitis occurs in sun-exposed skin that
has been in contact with psoralen-producing plants. This bio-
static photochemistry is utilized in a pathogen inactivation
technology (Intercept Blood System, Cerus Corp., Concord,
CA) for plasma and platelet concentrates in transfusion medi-
cine (4) where it prevents replication of potentially infectious
pathogens transmitted from the donor to the blood product. In
dermatology, PUVA is used to treat psoriasis, certain dermato-
ses, and cutaneous T-cell lymphoma (5). In these cases, the
psoralen is administered topically or systemically followed by
local or whole body UVA illumination. Treatment modalities
are diverse and may differ by psoralen derivative and/or by
doses of UVA light (6). Furthermore, PUVA is under clinical
investigation for the treatment of multiple other diseases
mostly involving uncontrolled cell proliferation (7). However,
although broadly applied in medicine, the biochemical conse-
quences of PUVA are poorly understood.
Psoralens are not clinically efficacious without UVA illumi-
nation, and despite its well documented photoreaction with
DNA, PUVA photochemistry is not specific for this particular
biologic target alone. In theory, photoexcited psoralens can
react with many other common biomolecules. Therefore, the
net effect of PUVA in a cellularmilieu is unlikely to be restricted
to consequences of its chemistry with solely DNA as was
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acknowledged already in the late seventies (8). This random
reaction with multiple biomolecules explains why the quest for
understanding PUVA and optimizing therapies has been
exceptionally challenging. For example, the systemic PUVA
treatment modality ECP is used to treat cutaneous T-cell lym-
phoma, and although clinically successful (9), themechanismof
action has remained elusive ever since its first application.
Researchers speculate that induction of apoptosis through
DNA damage causes priming of the immune system. However,
apoptosis induction alone is insufficient for the typical immu-
nomodulation caused by PUVA (10, 11). Despite this uncer-
tainty, ECP is used “off-label” for (auto)immune diseases
including GVHD, bronchiolitis after stem cell transplantation,
and Crohn’s disease (12, 13). But without comprehension of
definite biochemical mechanisms, both protocol uniformity
and outcome variability will remain problematic.
Adduct formation of photoexcited psoralens with targets
other than DNA (11, 14) is primarily with membrane compo-
nents (15, 16). Psoralens efficiently partition into lipid bilayers
(17, 18) where chemical reactions with double carbon bonds in
unsaturated acyl chains take place (19, 20). As a consequence,
rational hypotheses on the cell biological consequences of these
modifications have been postulated (21, 22), but mechanisms
explaining howmembranemodifications exactly impact down-
stream cell signal transduction are unknown.
We chose platelets as model cells to study this because they
have no nucleus, are easily isolated fromwhole blood, and con-
tain a complex signal transductionmachinery exemplary of key
signaling processes in most eukaryotic cells. Furthermore,
recent work has shown that PUVA significantly affects platelet
function in an in vitromodel of hemostasis (23). Our data now
show that PUVA can inhibit signal transduction in the phos-
phatidylinositol 3-kinase (PI3K) pathway by preventing effi-
cient plasma membrane recruitment of crucial effector kinases
such as Akt (alternative name, protein kinase B) and Bruton’s
tyrosine kinase (Btk).Our findings are not restricted to platelets
because T-lymphocytes in patient samples treated with ECP
displayed attenuation of Akt phosphorylation as well.
Results
PUVA Modifies Phospholipids by Covalent Adduct For-
mation—Adducts between nucleic acids and psoralens like
amotosalen or 8-methoxypsoralen (8-MOP) are formed in
nucleated cells, but chemistry with (phospho)lipids has been
described as well (15, 24). Mass spectrometry of platelet mem-
brane extracts confirmed that PUVA causes amotosalen-lipid
adduct formation, which was not found in control cells that
were incubated with this psoralen in the dark (Fig. 1, a and b).
All major phospholipid classes were targeted (Fig. 1c) provided
they contained acyl chains with unsaturated carbon bonds (19).
Fragmentation MS/MS spectra allowed identification of the
main adducts that formed, and Fig. 1d depicts exemplary
MS/MS data for PS(18:0/20:4), bisphosphorylated phosphati-
dylinositol (PIP2)(18:0/20:4), amotosalen, and their UVA-de-
pendent adducts.
PUVA Increases Lipid Order, Causing Inhibition of Protein
Binding—Because photochemical addition of psoralens is to
unsaturated carbon bonds, we hypothesized that PUVA causes
changes in the order of lipid phases because this is typically
controlled by acyl chain (un)saturation. To assess this, the envi-
ronment-sensitive fluorescent probe NR12S (25, 26) was used
in liposomes composed of PC(16:0/18:1). The emission peak of
NR12S shifts blue in liquid-ordered liposomes, causing a rise in
the generalized polarization (GP) value. In a validation experi-
ment, this was demonstrated by addition of cholesterol, which
is known to enhance lipid packing (Fig. 2a) (26). Ultraviolet A
light treatment of amotosalen-containing liposomes caused
apparent increases in lipid order similar to the addition of cho-
lesterol, suggesting that phospholipid-amotosalen adducts
tighten the acyl chain alignment.
Because disordered lipid microenvironments are important
for protein-membrane interaction (27, 28), two archetypical
membrane-adhering protein sequences, ALPS and -synuclein
(29, 30), were investigated for binding to PUVA-treated lipo-
somes. As expected, the ALPS peptide efficiently bound to
increasing concentrations of dark-treated control liposomes
enriched in PC(18:1/18:1) but not PC(16:0/18:1) (Fig. 2b) (29).
However, when the former were PUVA-treated, subsequent
ALPS binding was inhibited to levels similar to the negative
control. In a similar experiment, PUVA caused a significant
decrease in -synuclein binding to PS- and PC(18:1/18:1)-con-
taining liposomes (Fig. 2c). Collectively, these data show that
PUVA increases lipid order in liposomes and inhibits efficient
binding of lipid packing-sensitive protein sequences.
PUVA Affects Akt and Btk Plasma Membrane Binding and
Subsequent Signal Transduction—During platelet activation,
essential interactions between membrane (phospho)lipids and
cytoplasmic soluble proteins take place. These then relay sig-
nals to secondary messenger molecules, establishing successful
primary hemostasis. Because PUVA affects protein interaction
with model liposomes, we questioned whether this membrane
binding of key cytoplasmic signaling proteins like Akt and Btk
was intact in PUVA-treated platelets. To activate the initiating
PI3K pathway in platelets, the collagen GPVI or the thrombin
PAR1 was stimulated. Membrane binding of Akt and Btk was
assessed by Western blotting of isolated membrane fractions.
Significantly less Akt and Btk was found in PUVA versus paired
untreated controls, pointing to defects inmembrane binding in
live cells as well (Fig. 3a). This defective binding moreover
caused significant decreases in subsequent Akt phosphoryla-
tion, a major event in the PI3K signal transduction pathway
(Fig. 3b) (31).
Binding ofAkt andBtk to the activatedmembrane requires at
least increased levels PI(3,4,5)P3, which is produced by phos-
phorylation of PIP2 by PI3K. Quantitative mass spectrometry
on membrane extracts ruled out that PI(3,4,5)P3 formation is
abnormal in PUVA-treated resting and activated platelets (Fig.
4a). Furthermore, the relative amount of PIP2-amotosalen
adducts to total PIP2 was only 1.2%, confirming that direct
effects on the PI3K substrate were unlikely to cause decreased
Akt membrane recruitment and phosphorylation. Further-
more, signal transduction in the concurrent phospholipase C
(PLC) pathway was not affected by PUVA because the level of
pleckstrin phosphorylation (Fig. 4b) and calcium release (data
not shown) were normal in response to GPVI and PAR1 stim-
ulation. Of note, platelet activation by another thrombin ana-
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logue that specifically targets PAR4 instead of PAR1 was not
affected by PUVA and led to normal Akt phosphorylation (Fig.
4c). This is important because it demonstrates that the intrinsic
potential to phosphorylate Akt is still present in PUVA-treated
cells but depends on the kind of activatory input. Together,
these data show that, despite generic adduct formation of pso-
ralenwith acyl chains, consequences for signal transduction are
relatively selective and specific.
Platelet Integrin Activation Is Decreased by PUVA—Down-
streamof the investigated signaling circuit, platelets respond by
activation of integrin IIb3. Integrin activation of PUVA-
treated platelets was investigated with flow cytometry using the
conformation-sensitive monoclonal antibody PAC-1 (32).
PUVA caused a significant decrease in integrin activation fol-
lowing stimulationwith increasing doses of the thrombin PAR1
(effective half-maximal concentration (EC50), 8.4  1.1 versus
4.3  1.1 M) or the collagen GPVI (EC50, 1.61  0.85 versus
0.26  0.21 g/ml) receptor agonists (Fig. 5, a and b). In line
with the Akt phosphorylation data, activation through PAR4
was normal (EC50, 50  1 versus 58  1 M) (Fig. 5c). As a
control, the plasma membrane expression levels of the recep-
tors GPVI and PAR1 was determined in flow cytometry and
found to be normal (Fig. 5d).
PUVA Decreases Phosphorylation of Akt in T-lymphocytes
from GVHD Patients—As a model for PUVA treatment of
nucleated human cells, leukocytes were isolated from healthy
consenting volunteers. The T-lymphocytes were activated by
anti-CD3/CD28 beads. The effect of PUVAonT-cell activation
FIGURE1.Chromatographyandmassspectrometry identifiedadductsbetweenplateletmembranephospholipidsandthepsoralenamotosalenafter
PUVA. a, extracted ion LC-MS chromatograms (m/z 1418.7073 10 ppm) of PUVA-treated platelets (red tracing) indicate de novo formation of PIP2(18:0/20:
4)-amotosalen covalent adducts. Control extracts (blue tracing; overlaid) were not UVA-illuminated. b, exemplary accuratemass spectrum indicating covalent
adducts of amotosalen and PIP2(18:0/20:4) in the PUVA-treated (red) spectrum. Non-illuminated control (blue; overlaid) samples were devoid of adducts. c,
amotosalen adducts were found in all major phospholipid classes using a search-by-mass strategy. Lipid-amotosalen adducts were confirmed by MS/MS
analysis, and the AUCof the chromatographic peakwas plotted for PC (open bars), phosphatidylethanolamine (green), PI (blue), and PS (yellow). Data represent
mean, and error bars represent S.D. (n 4). d, exemplary fragmentationMS/MS spectra of PS(18:0/20:4) (green annotations), PIP2(18:0/20:4) (blue annotations),
andamotosalen (redannotations) in the leftandmiddle panels, respectively. Letter annotations refer to intactphospholipid (a) or amotosalen (A) and fragments
of phospholipid (b–d) or amotosalen (B, C) corresponding to the structures given in the center of the panel. The two right panels depict characteristic adducts
of these phospholipids with amotosalen.
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was determined for 8-MOP and amotosalen in a paired exper-
iment. The data show that both psoralens dose-dependently
inhibited phosphorylation of Akt (Fig. 6, a and b), which was
not caused by immediate cell death (data not shown). The data
show that amotosalen was more efficient than 8-MOP, requir-
ing lower concentrations to achieve half-maximal inhibition.
To confirm whether Akt activation is affected in clinically rel-
evant tissue, buffy coat cells from GVHD patients enrolled in a
clinical efficacy study were collected before and after ECP. In
these samples, Akt activation in T-lymphocytes was also signif-
icantly decreased (Fig. 6, c and d). Together, these data show
that PI3K-dependent signaling is affected by PUVA in cells
other than platelets and in the clinical setting of ECP treatment.
Discussion
Despite its widespread clinical use, many aspects of PUVA’s
mode of action have remained uncertain. Our data show for the
first time that PUVA treatment specifically inhibits the PI3K-
Akt pathway by interfering with efficient recruitment of effec-
tor kinases Akt and Btk to the activated plasma membrane in
response to specific stimuli. Our model (Fig. 7) suggests that
psoralen-phospholipid adduct formation in the plasma mem-
brane prevents efficient interaction between effector proteins
specifically interacting with microenvironments of decreased
lipid packing harboring PI(3,4,5)P3.
Covalent binding of photoexcited psoralen to unsaturated
fatty acids has been described before in cell-free test tubes
and in cell extracts (19, 20, 24). Our mass spectra of PUVA-
treated platelet extracts confirm covalent reaction with unsat-
urated acyl side chains. All investigated phospholipid classes
formed adducts with the amotosalen, indicating no preference
for the hydrophilic headgroup. Despite this seemingly unspe-
cific photochemistry, signal transduction inhibition was
remarkably specific for the PI3K pathway. Phosphorylation of
Akt was decreased, but the concurrent PLC axis showed no
defect even though both pathways utilize the same PI(4,5)P2
substrate. Furthermore, PI3K activity was not directly affected
by the presence of free amotosalen and its adducts with
PI(4,5)P2 because PI(3,4,5)P3 levels were normal in response to
platelet activation and because these particular adducts were
not abundant. Consequently, specific modification of only
inositides is not underlying the PI3K signal transduction defect.
Instead, PUVA inhibits normal plasma membrane recruit-
ment of Akt and Btk in the presence of normal PI(3,4,5)P3 lev-
els, suggesting that the interaction is dependent on auxiliary
facilitators. Because unsaturated fatty acids are the prime target
of PUVA chemistry, such facilitators thus require normal (lev-
els of) fatty acyl unsaturations to fulfill their role. Plasmamem-
brane binding of small effector kinases is well studied, and even
FIGURE 2. PUVA treatment of liposomes increased the order of lipid phases and inhibited interactionwith lipid packing-sensitive peptides. a, the GP
value is a relative measure of lipid order calculated from the fluorescence of the environment-sensitive probe NR12S at two emission wavelengths. Increased
GP values indicate increases in lipid packing. Liposomesprepared fromPC(16:0/18:1)were incubatedwith amotosalen and treatedwithUVA (PUVA; closed bar)
or not (CTR; open bar). Cholesterol was added as a positive control for increased lipid order. Data are mean with S.D. as error bars (n 4). b, binding of ALPS to
PC(18:1/18:1)-enriched liposomes (cyan) or to PC(16:0/18:1) liposomes (magenta) is shown. All contained amotosalen and were left in the dark (f) or treated
with UVA light () prior to incubation with ALPS. The corrected peak fluorescence signal (F  F0) of the covalently attached NBD moiety was used and is
depictedas a functionof lipid concentration.Data aremeanwithS.D. as error bars (n6). c, bindingof-synuclein to control liposomes (CTR) containingmainly
18:1/18:1 phospholipids (cyan) is compared with paired PUVA-treated counterparts and negative controls containing mainly 16:0/18:1 phospholipids
(magenta). Also here, NBDwas covalently attached, and the corrected peak fluorescence signal (F F0) is shown. Data aremeanwith S.D. as error bars (n 5).
p values are from one-way analysis of variance with Tukey’s multiple comparison test.
Effects of Psoralen and UVA Light on Signal Transduction
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though it is assumed to be primarily between the PH domain
sequence KXn(K/R)XR (33) and PI(3,4,5)P3, additional factors
(in)directly support binding. For instance, the related PH
domains of PLC1 and GRP1 are known to harbor amino acids
that penetrate the inner hydrophobic core of the membrane
(34, 35). Such membrane insertion often requires the targeted
membrane compartment to be less tightly packed (29, 36). Now
our data show that binding of packing-sensitive probes ALPS
and -synuclein to model bilayers is hampered by PUVA. This
indicates that amino acid insertion into the membrane core
facilitated by unsaturated phospholipids is inhibited by PUVA.
We thus hypothesize that lipid packing is the additional factor
that cooperatively strengthens Akt and Btk binding as sug-
gested by the coincidence detection (37) hypothesis of PH
domain interactions with the plasmamembrane. Our data pro-
vide the first proof in live cells that the acyl side chain milieu of
phospholipids co-determines binding success of major PH
domain-containing effector kinases in the presence of normal
PI(3,4,5)P3 levels.
The extent of Akt and Btk inhibition by PUVA, however,
varies with the stimulus. Integrin IIb3 activation was most
affected following GPVI stimulation, less by PAR1, and not at
all by PAR4. This shows that the defect is not restricted to either
G-protein-coupled or immune receptor activation. It also
means that the integrin conformational machinery is not
affected directly by PUVA and able to respond normally if sig-
nals come in correctly from the upstream cue. How this varia-
bility in response is established, however, remains uncertain.
Maybe the separate ligand-receptor circuits reside in plasma
membrane microdomains of specific phospholipid composi-
tion (38) that is variably susceptible to modifications by PUVA.
This follows the biochemical dogma of PI3K-dependent signal-
ing stating that PI(3,4,5)P3 molecules are scaffolding molecules
restricted in space and time for controlled signalosome con-
struction (39). The experimental setting allows activation
through a single receptor-ligand couple, resulting in a distinct
identifiable signal. However, in a real life physiologic environ-
ment, multiple extracellular chemicals act in concert at varying
concentrations in space and time. Therefore, the net effect of
PUVA on the diverse tissues that are clinically treated is diffi-
cult to predict based on our findings. However, because many
signaling pathways rely on membrane recruitment, the output
of PUVA-treated tissue in response to physiologically relevant
chemicals will be undoubtedly altered.
In platelets, this altered output presents as delayed thrombus
formation on immobilized collagen in vitro (23). Experimental
inhibition of PI(3,4,5)P3-dependent signaling in platelets
indeed shows significant function defects for instance inmouse
FIGURE 3. PUVA treatment specifically affected PI3K signal transduction by impairing recruitment of Akt and Btk. a, platelets were activated via the
collagenGPVI or the thrombin PAR1, and themembrane fractionwas analyzed byWestern blotting and densitometry. Antibodies to total Akt (Akt) or total Btk
(Btk) were used. Loadingwas controlled by reprobingwith anti-integrin IIb. Molecular marker bands to the right (Akt) or in themiddle (Btk) of themembrane
represent molecular masses of 75 and 50 kDa. PUVA treatment versus control is indicated on top of the panels. The decrease in mean protein band density of
PUVA-treated samples relative to untreated paired controls is shown in the bar graphs (mean with error bars representing S.D., n  3). Null change is
emphasizedby thehorizontal dashed line.b,whole lysatesof activatedplateletswereanalyzedbyWesternblottinganddensitometryusingantibodies toP-Akt.
Loadingwas controlled by reprobingwith total Akt (Akt). Molecular marker bands in the left lanes representmolecular masses of 75 and 50 kDa. To control for
PI3K pathway specificity, paired experiments in the presence of 0.5 M Wm were performed. The decrease in mean protein band density of the ratio of
phosphorylated kinase to total kinase (meanwith error bars representing S.D., n 6) in PUVA-treated platelets relative to untreated paired control is shown in
the bar graph. Null change is emphasized by the horizontal dashed line.
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models of Akt isoform deficiency (31), PDK1 deficiency (40), or
PI3K isoform deficiency (41). In human B-cell malignancy, Btk
inhibition by ibrutinib is clinically successful but increases the
risk of bleeding by platelet inhibition (42). Platelets are cur-
rently treated by PUVA in certain blood banks in Europe to
prevent transmission of pathogens during transfusion. This
treatment efficiently reduces pathogen and white blood cell
proliferation by damaging their DNA. Originally platelets were
believed to be unsusceptible to PUVA because they do not con-
tain a nucleus. Our findings have now revealed the mechanism
of decreased function caused by side effects of PUVA and unre-
lated toDNAdamage. The clinical consequences of transfusing
psoralen-modified phospholipids are unknown but worthwhile
investigating.
Our findings also have consequences for other fields that
commonly apply PUVA. The exact biochemical drivers of
PUVA’s clinical success in skin pathologies or GVHD for
instance remain poorly understood. We propose a substantial
role for selective PI3K axis inhibition given the results of the
buffy coat samples from our GVHD patient that clearly dem-
onstrate reduced Akt phosphorylation. However, this single
readout merely demonstrates attenuation of just one effector
kinase (Akt), in one cell type, and to one ligand-receptor com-
bination. The exact cellular composition of PUVA-treated
tissue by type and number as well as their individual suscep-
tibility to PUVA will eventually determine the response in a
relevant physiological environment. Further study will thus
require a systems approach (43) to unravel the dependence
of relevant ligand-receptor couples to PUVA and combine
the findings in an integrated view, ideally also taking into
account effects on DNA replication and transcription where
possible.
In conclusion, our research shows that PUVA selectively
inhibits recruitment of kinases Akt and Btk to activated plasma
membranes. This suggests that unsaturations in the plasma
membrane co-determine kinase-membrane binding. We fur-
thermore propose that the variable susceptibility of ligand-re-
ceptor couples to PUVAcontributes to complex rewiring of cell
FIGURE 4. Formation of PI(3,4,5)P3, phosphorylation of Akt in response to PAR4 stimulation, and the phospholipase C pathwaywere not affected by
PUVA. a, the amount of PI(3,4,5)P3(18:0/20:4) in platelet lipid extracts was determined by peak area (AUC) relative to that of the internal standard (AUC, IS).
Plateletswere activated via the collagenGPVI or the thrombin PAR1. Untreated controls (open bars) andPUVA-treated samples (closed bars) are shown. Resting
platelets were incubatedwith vehicle only. Mean data and error bars representing S.D. are shown (n 4). b, whole lysates of activated platelets were analyzed
by Western blotting using antibodies to phosphorylated tyrosines (P-Tyr). Loading and specificity were controlled by reprobing with anti-pleckstrin (PLK)
antibodies. Molecular marker bands in the left and right lanes represent molecular masses of 50 and 35 kDa. Paired control samples for resting platelets were
incubated with the respective vehicle buffers. c, platelets were activated via the thrombin PAR4, and whole lysates were analyzed by Western blotting using
antibodies to P-Akt. Loadingwas controlled by reprobingwith total Akt (Akt). Molecularmarker bands in the left lanes representmolecularmasses of 75 and 50
kDa. To control for PI3K pathway specificity, paired experiments in the presence of 0.5MWmwere performed. The decrease inmean protein band density of
the ratio of phosphorylated kinase to total kinase (mean data and error bars representing S.D., n 3) in PUVA-treated platelets relative to untreated paired
control is shown in the bar graph. Null change is emphasized by the horizontal dashed line.
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and tissue fate, explaining the complexity in output and in clin-
ical success.
Experimental Procedures
Materials—Reagents were obtained from the following
sources: wortmannin (Wm), anti-phosphorylated Akt (P-Akt)
(clone D25E6), anti-total (pan) Akt (40D4), anti-total Btk
(C82B8), phosphotyrosine monoclonal antibody (P-Tyr-102),
and secondary peroxidase-labeled antibodies (Cell Signaling
Technologies,Danvers,MA); thrombin receptor PAR1-activat-
ing hexapeptide SFLLRN, 4-chloro-7-nitrobenzofurazan
(NBD) chloride, tris(2-carboxyethyl)phosphine, RPMI 1640
medium without phenol red, L-glutamine, 8-MOP, and inter-
leukin-2 (IL2) (Sigma-Aldrich); thrombin receptor PAR4-acti-
vating hexapeptide AYPGKF (Anaspec, Waddinxveen, The
Netherlands); collagen receptor GPVI-activating cross-linked
collagen-related peptide (University of Cambridge, Cambridge,
UK); Halt protease and phosphatase inhibitor mixture
(Thermo Scientific,Waltham,MA);MeSADP (Santa Cruz Bio-
technology, Dallas, TX); anti-pleckstrin antibody (ab17020)
and human wild type -synuclein (ab51188) (Abcam, Cam-
bridge, UK); andNBD iodoacetamide (IANBD) and Dynabeads
humanT-activatorCD3/C28 (LifeTechnologies). All phospho-
lipids and cholesterol were purchased dissolved in chloroform
(Avanti Polar Lipids, Alabaster, AL). ALPSpeptidewas custom-
made (Proteogenix, Schiltigheim, France) and based on the first
38 amino acids of the GMAP210 protein (44) except for the
N-terminalmethionine, whichwasmutated to cysteine to allow
targeted labeling with NBD. Ficoll-Paque Premium (d 1.077
g/ml at 20 °C) was obtained from GE Healthcare. Blood group
AB serum was provided by the Belgian Red Cross-Flanders
blood bank. The environment-sensitive NR12S probe is a Nile
Red derivative and a kind gift from Dr. Klymchenko (Stras-
bourg University, France) (25, 26).
PUVA Treatment—PUVA treatment of platelets, liposomes,
and peripheral blood mononuclear cells (PBMCs) was with the
Intercept Blood System pathogen inactivation technology
using amotosalen or 8-MOP as the active photosensitizing pso-
ralen. Ultraviolet A light in the wavelength range 320–400 nm
was delivered to the samples in a closed and calibrated illumi-
nation device.
Platelet concentrates for transfusion were prepared from
human voluntary whole blood donations using the stan-
dardized buffy coatmethod (45), which is by pooling of six buffy
coats and resuspension in additive solution (SSP, Macoph-
arma, Tourcoing, France) as described (23). To generate paired
samples, two platelet concentrates were pooled, mixed, and
split again in two equivalent volumes. One volume remained
untreated (control), and the other was PUVA-treated in
accordance with the instructions of the Intercept Blood System
manufacturer (46, 47). For this, the platelet concentrate was
transferred to an illumination bag while 17.5 ml of amotosalen
(final 150 M) solution was added followed by UVA illumina-
tion at a dose of 3.9 J/cm2 for 260 s on average. Following over-
night incubation on an orbital shaker at room temperaturewith
a compound adsorption device to remove unreacted amoto-
salen and its photoproducts, platelet concentrates were trans-
FIGURE 5. Integrin IIb3 activation was inhibited in PUVA-treated platelets following stimulation of GPVI and PAR1 but not PAR4 receptors. Paired
platelet samples were treatedwith PUVA () or not (CTR;) and then incubatedwith increasing doses of agonists to PAR1 (a), GPVI (b), or PAR4 (c). Activation
of integrinIIb3 wasmeasuredwith flow cytometry using labeled PAC-1 antibody. The data were fitted by non-linear regression. EC50 values were calculated
from these fits and are depicted in the inset tables. Data are shown as mean with error bars representing S.D.; the number of repeats is indicated in the inset
tables. d, receptor expression levels were measured by flow cytometry. Paired platelet samples treated with PUVA or not (CTR) were incubated with labeled
monoclonal antibodies. Median fluorescence intensities (mean FI) of anti-GPVI and anti-PAR1 in resting (open bars) and activated (closed bars) platelets are
shown (mean with error bars representing S.D., n 3).
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ferred to a storage bag. Storage was under standard blood bank
conditions. Experiments on platelets were performed 16–24 h
after UVA illumination using low volume samples taken
through sterile welded connections under a laminar flow hood.
Signal TransductionAnalysis—Platelet samples werewashed
in Tyrode’s buffer (5 mM HEPES, pH 7.4, with 136.5 mM NaCl,
2.7mMKCl, 11.9mMNaHCO3, 0.4mMNaH2PO4, 1mMMgCl2,
and 0.1% (w/v) D-glucose) as described (48). Washed platelets
were rested for maximally 30 min at 37 °C prior to activation
with the indicated agonists and incubation times. Activation
through PARs for measurement of phosphorylation down-
stream of PI3K activation was in conjunction with 10 M
MeSADP. Activated platelets were lysed in ice-cold buffer (50
mM Tris, pH 8.0, with 100 mM NaCl, 0.5% (v/v) octylphenoxy-
polyethoxyethanol (Igepal-CA630), 0.4% (w/v) sodium dodecyl
sulfate (SDS), 10mM activatedNa3VO4, andHalt proteasemix-
ture) andmixed. Separation of plateletmembrane fractionswas
performed by ultracentrifugation as described by Badolia et al.
(49). In brief, following platelet activation, the reaction was
stopped by the addition of Halt protease mixture (final 2).
Four freeze/thaw cycles in liquid nitrogen were performed
next. Lysates were centrifuged at 1500 g for 10 min at 4 °C to
precipitate poorly lysed cell remnants. The supernatant was
centrifuged in an ultracentrifuge at 100,000  g for 30 min at
4 °C. The supernatant contained the cytosolic fraction and was
kept stored at 20 °C. The pellet, which contained the mem-
brane fraction and cytoskeleton, was rinsed with 1 ml of ice-
cold Tris-buffered saline (TBS) (pH 7.4; 25 mM Tris with 150
mMNaCl and 2mMKCl) containing 1% (v/v) Triton X-100 and
2 (final concentration) Halt protease mixture before it was
resuspended in 100 l of the same buffer. These suspensions
were again centrifuged at 15,000 g for 10 min at 4 °C to pre-
cipitate the cytoskeleton. The supernatant contained themem-
brane fraction. Sample protein concentration was determined
using a bicinchoninic acid kit (ThermoScientific, Rockford, IL).
Platelet samples (membrane fraction or whole platelet
lysates) were loaded on 4–15% polyacrylamide Tris-glycine
TGX gels in reducing Laemmli sample buffer.Western blotting
was onto precut nitrocellulose membranes. Primary and sec-
ondary antibodies to blotted targets were prepared in TBS with
0.1% (v/v) Tween 20 and 5% (w/v) skimmedmilk. Reprobing of
membranes was by incubation for 30 min at 60 °C in Western
reprobing buffer (50 mM Tris, pH 7.0, 2.0% (w/v) SDS, and 100
mM -mercaptoethanol). Bound antibody was detected with
enhanced chemiluminescence and an automated imaging sys-
tem (ChemiDoc MP) equipped with a charge-coupled device
camera and analysis software (ImageLab v4.0.1) for densitom-
etry (all reagents, hardware, and software from Bio-Rad).
Lipid Extraction and Lipid Sample Preparation—The sol-
vents used for the lipid extraction and LC-MS separation were
HPLC grade chloroform, ultra-LC-MS grade water, and ultra-
LC-MS grade methanol (Biosolve, Valkenswaard, The Nether-
lands). HPLC grade ammonium formate, HCl, andHPLC grade
methyl tert-butyl ether were from Sigma-Aldrich. Phosphoi-
nositides from platelet lipid extracts were derivatized and ana-
lyzed as described (50) with minor modifications. In brief, 3
volumes of chloroform/methanol (1:2, v/v) were added to 1
volume of platelet suspension for extraction of neutral lipids.
The samples were vortex-mixed followed by centrifugation at
13,000  g for 2 min. The supernatant was transferred to an
LC-MS vial and used as such for analysis of phospholipids and
phospholipids in complex with amotosalen. Internal standards
PI(4,5)P2(17:0/20:4) and PI(3,4,5)P3(17:0/20:4) were added at 5
g/ml to the remaining pellet. A volume of 1365 l of methyl
tert-butyl ether, methanol, and 2 M HCl (200:60:13, v/v/v) was
used to resuspend the fraction followed by incubation for 15
min at room temperature with intermittent mixing. Next, 250
l of 0.1 M HCl was added, vortex-mixed, and centrifuged at
6,500 g for 2min. The upper organic phase was transferred to
a new tube, and 500 l of prederivatization wash solution
(lower phase of methyl tert-butyl ether, methanol, and 0.01 M
HCl (100:30:25, v/v/v)) was added. The sampleswere again cen-
trifuged at 6,500 g for 2 min, and the upper phase was trans-
ferred for derivatization. To this, 50 l of 2 M trimethylsilyldi-
azomethane in hexanewas added andmixed for 10min at room
temperature followed by addition of 6 l of glacial acetic acid
(all Sigma-Aldrich) to stop the methylation reaction. Next, 500
FIGURE6.PhosphorylationofAktwasdecreasedafterPUVAtreatmentof
T-lymphocytes. a and b, dose escalations of 8-MOP (a) or amotosalen (AS) (b)
were added to isolated PBMCs from healthy donors and subsequently illumi-
nated with UVA light or not as indicated on top of each panel. The condition
without psoralen contained vehicle solution andwas used as a negative con-
trol. c, PBMCs were isolated from clinical buffy coat samples before (pre) and
after (post) ECP treatment for GVHD. T-lymphocyte activation in the presence
of 0.5 M Wm was used to control for specificity of the PI3K axis. a–c, T-lym-
phocytes were activated by receptor ligation in the presence of IL2 followed
byWestern blotting of whole cell lysates. Antibodies to P-Akt were used, and
membraneswere reprobed for total Akt (Akt) to control for loading.Molecular
marker bands in the left lanes representmolecularmasses of 75 and 50 kDa. d,
the mean decrease in the P-Akt over Akt signal ratio in samples post-ECP
relative to pre-ECP is depicted (mean with error bars representing S.D., n 3
different ECP treatments). Null change is emphasized by the horizontal
dashed line.
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l of postderivatization wash solution (upper phase of chloro-
form/methanol/water (120:60:45, v/v/v)) was added, vortex-
mixed, and centrifuged for 5min at 1,500 g. The upper phase
was transferred to a high recovery glass vial and dried down in a
centrifugal vacuum evaporator (MiVac duoconcentrator,
Genevac, Ipswich, UK) at 37 °C. The dried sample was recon-
stituted in 50 l of chloroform/methanol (1:2, v/v) before
injection.
Analysis of (Phospho)lipids—Lipid analysis was based on high
resolution liquid chromatography coupled to high resolution
quadruple time-of-flight (TOF)mass spectrometry (51, 52). For
lipidomics analyses, a 1290 Infinity LC system (Agilent Tech-
nologies, Waldbronn, Germany) was used. Lipid extracts were
analyzed on an Acquity UPLC BEH Shield RP18 column (2.1
100mm; 1.7m;Waters,Milford,MA) placed in a Polaratherm
9000 series oven (Selerity Technologies, Salt Lake City, UT) at
80 °C. Elution was carried out with a multistep gradient of
mobile phase A (20 mM ammonium formate, pH 5.0) and
mobile phase B (methanol) starting from 50% B to 70% B in 5
min followed by a slow gradient of 70–90% B in 30min.Mobile
phase B subsequently reached 100% in 0.1 min where it was
maintained for an additional 5 min. The flow rate was 0.5
ml/min, and the injection volume was 10 l for both positive
and negative electron spray ionization (ESI) measurements.
The whole system was allowed to re-equilibrate under starting
conditions for 15 min. For measurement of derivatized phos-
phoinositides, elution was optimized using the same mobile
phases at a flow rate of 1.0 ml/min, starting from 50% B to 85%
B in 5 min followed by a very slow gradient of 85–90% B in 15
min. At the end of the analysis, mobile phase B reached 100% in
2 min where it was maintained for an additional 3 min. High
resolution accurate mass measurements were obtained on an
Agilent 6550 quadruple TOFmass spectrometer equippedwith
a dual Jetstream ESI source. The instrument was operated in
both positive and negative ESI modes. Needle voltage was opti-
mized to3.5 kV; the drying and sheath gas temperatures were
set to 290 and 400 °C, respectively; and the drying and sheath
gas flow rates were set to 13 and 12 liters/min, respectively.
Data were collected in centroid mode fromm/z 100 to 3,200 at
an acquisition rate of two spectra/second in the extended
dynamic rangemode (2GHz), offering an in-spectrumdynamic
range of 105 and a resolution of20,000 full-width half-maxi-
mum in the lipid m/z range. MS/MS experiments were per-
formed in targeted MS/MS mode. The quadrupole was oper-
ated atmedium resolution, and the collision energy was fixed at
either 20 or 35 eV. Study samples were analyzed in randomized
FIGURE 7. PUVA directly interferes with PI(3,4,5)P3-dependent processes. Stimulation of platelet G-protein-coupled receptors like PAR1 and PAR4 or
platelet immune receptors like the collagen receptor GPVI in complex with Fc receptor (FcR) results in recruitment of PH domain-containing effector
molecules like Akt and Btk to the spatiotemporally restricted scavenger phospholipid PI(3,4,5)P3 in the cytosolic leaflet of the membrane. This causes phos-
phorylation of such targets (pAkt/pBtk), their release from the confined plasmamembrane space, and execution of numerous cellular functions downstream.
Following PUVA, however, covalent modification of unsaturated acyl side chains in all phospholipid classes attenuates efficient recruitment to PI(3,4,5)P3 in
response to certain (PAR1 and GPVI) but not all (PAR4) ligand-receptor couples.
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order. Samples were kept at 4 °C in the autosampler tray while
waiting for injection.
Abundances (area under the curve (AUC)) of lipid species
were extracted by the Find by Ion extraction algorithm in the
MassHunter Qualitative Analysis 7.0 software package (Agi-
lent Technologies) using predefined mass (10 ppm) and
retention time extraction windows (15 s). The Agile integra-
tor was used with an absolute peak height cutoff of 1,000
counts.
Molecular formulas, based on accurate mass, isotopic abun-
dance, and spacing both in positive and negative ionization
modes, were complemented with accurate mass database
searching in an in-house-built database (populated with LIPID
Metabolites And Pathways Strategy (MAPS) and Human
Metabolome Database (HMDB) entries and theoretical lipid
structures) and MS/MS measurement in both modes. Lipid
fragmentation mechanisms and spectra in both positive and
negative ionization modes were equal to those reported in the
literature (52). Each lipid class displays characteristic fragment
ions in positive and/or negative ESI mode. Other parameters
such as lipid elution behavior and adduct formation interpreta-
tion further assisted in the identification. Regarding phosphoi-
nositides, LC-MS cannot discriminate between PIP2 isomers
differing in the position of phosphates on the inositol ring. For
trisphosphorylated PI(3,4,5)P3, the only known isomer is
PI(3,4,5)P3. Throughout the paper, the nomenclature of the
International Lipid Classification and Nomenclature Commit-
tee, i.e. the “comprehensive classification system for lipids,” has
been used (53–55).
Flow Cytometry—Membrane expression of activated
integrin IIb3 was analyzed with an acoustic focusing
Attune flow cytometer (Life Technologies) using fluoresce-
in-labeled PAC-1 monoclonal antibody (BD Biosciences).
Platelets were incubated with 5% (v/v) PAC-1 and the indi-
cated agonists or the respective vehicle buffer for 10 min at
room temperature in HEPES-buffered saline, pH 7.4, with
1.0 mM MgSO4 and diluted a thousand-fold immediately
before readout according to previously published work (56).
Signals of the isotype antibody controls were used to set
threshold gates including 0.5% of 10,000 negative events. A
total of 10,000 events staining positive for the platelet
marker CD61 (allophycocyanin-labeled anti-CD61, Life
Technologies) were measured.
Lipid Packing Analysis in Liposomes—Liposomes were pre-
pared by mixing the (phospho)lipids from their stock solutions
in chloroform and drying under nitrogen gas. Next, these were
rehydrated inHKac buffer (50mMHEPES, pH 7.2, with 120mM
potassium acetate, 1 mM MgCl2, and 1 mM dithiothreitol) fol-
lowed by five freeze/thaw cycles in liquid nitrogen and a 37 °C
water bath. The samples were sonicated for 15 min at room
temperature in a bath at 80 kHz. Liposome preparations were
kept under nitrogen gas to avoid oxidation and were prepared
fresh for every experiment. UVA treatment was similar to that
of platelet concentrates.
The order of lipid phases was analyzed using the environ-
ment-sensitive NR12S probe (25, 26). Probe and lipid concen-
trations were optimized first in separate validation experi-
ments. First, liposomes of PC(16:0/18:1) with orwithout 35mol
% cholesterol containing 150MamotosalenwereUVA-illumi-
nated or not. Next, 50 M of liposomes by lipid content were
mixed with 0.1 M NR12S and allowed to equilibrate for 7 min
in the dark at room temperature. Fluorescencewasmeasured in
a fluorescence spectrophotometer (Tecan, Männedorf, Swit-
zerland) at 580- and 620-nm emission wavelengths using
510-nm excitation filters. The emission peak of NR12S shifts
blue when partitioned to lipid phases of increased order. The
fluorescence intensities at each emission wavelength were used
to calculate a GP value (57). This is a relative measure between
1 (most ordered) and1 (least ordered).
Binding experiments of the peptidic lipid-packing sensors
-synuclein and ALPS were based on the work by Vanni et al.
(29) and Pranke et al. (30). First, the peptides were covalently
labeled with NBD to their N termini. -Synuclein at 1 mg/ml
was labeled by incubation with 0.5 mM NBD chloride in citrate
buffer, pH 7.0, with 1 mM EDTA for 24 h in the dark at room
temperature. The neutral pH renders the reaction specific for
the peptide N terminus, avoiding labeling auxiliary amines in
the amino acid sequence (58). The reactionmixture was then
re-equilibrated to HEPES-buffered saline, pH 7.4, with 5 mM
KCl and 1 mM MgSO4 by desalting column buffer exchange
(Zeba Spin columns, Thermo Scientific). The ALPS peptide
contained just one cysteine (at the N terminus) and was kept
in a reducing environment (10-fold molar excess of tris(2-
carboxyethyl)phosphine). Labeling was to that free N-termi-
nal thiol using IANBD at a molar ratio of IANBD of 10:1 in
HK buffer (50 mM HEPES, pH 7.2, with 120 mM potassium
acetate) for 2 h at room temperature in the dark. The reac-
tion mixture was dialyzed (membrane molecular weight cut-
off, 2,000) to 4 liters of HK buffer during 24 h at 4 °C. The
degree of labeling for both peptides was determined by opti-
cal absorbance at wavelengths for peptides and bound and
free label.
Liposome (phospho)lipid composition was different in
ALPS-NBD and -synuclein-NBD binding experiments and
was based on the literature (29). For ALPS-NBD binding, lipo-
somes were composed of either 85mol % PC(18:1/18:1) with 15
mol % glycerol(18:1/18:1) or 100 mol % PC(16:0/18:1) as a neg-
ative control. ALPS-NBD (0.17 M) was added to a serial dilu-
tion of PUVA- or control-treated liposomes in HKac buffer.
PUVA treatment was with 60 M amotosalen, and unlabeled
ALPS was used for background correction (F0). Fluorescence F
(emission, 535 nm) wasmeasured at 37 °C (excitation, 485 nm).
Liposomes for binding experiments with -synuclein-NBD
contained either PC(18:1/18:1) with PS(18:1/18:1) or PC(16:0/
18:1) with PS(16:0/18:1) always in a 1:1 molar ratio in the pres-
ence of 50 mol % cholesterol and 10 mol % egg PC (30). Incu-
bation, readout, and analysis were the same as for ALPS-NBD
except that PUVA treatment was with 150M amotosalen, and
the peptide concentrationwas 0.25M. BothNBD-labeled pep-
tides were not exposed to UVA light because binding experi-
ments were performed after PUVA.
T-cell Activation—PBMCs were prepared by Ficoll gradient
centrifugation of buffy coats from healthy donors. Isolated
PBMC preparations were washed three times in sterile phos-
phate-buffered saline, pH 7.4, by soft centrifugation to remove
contaminating platelets. Finally, the cells were resuspended in
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phenol red-free RPMI 1640mediumwith 2mM L-glutamine, 10
mM HEPES, and 10% (v/v) AB human serum and rested for 2 h
at room temperature. The rested cells were resuspended to
40,000 leukocytes/l in Tyrode’s buffer andmixedwith 8-MOP
or amotosalen in a final amount of 60 106 leukocytes. Follow-
ing PUVA, T-cells were activated in Tyrode’s buffer with 2.5
106 CD3/CD28 human T-activator Dynabeads/106 leukocytes
in the presence of 10 ng/ml IL2 for 30min at 37 °C on a rotator.
Cells were lysed with ice-cold lysis buffer and centrifuged at
20,000 g for 3 min. Supernatant was analyzed by SDS-PAGE
Western blotting in reducing sample buffer. Cell viability was
unaltered by PUVA during the course of T-cell receptor activa-
tion as monitored by Sytox Green (Life Technologies) staining
in flow cytometry.
Extracorporeal Photopheresis Samples—Apatient enrolled in
a clinical trial for ECP at the Hospital Network Antwerp (Bel-
gium) for the treatment of chronic GVHD gave informed con-
sent for sampling of cells from the buffy coat suspension before
and after ECP. The study was approved by the hospital’s ethics
committee (approval number 4591). The ECP procedure
involved a leukapheresis (Spectra Optia, Terumo BCT, Lake-
wood, CO) yielding a buffy coat cell suspension that was diluted
with saline in an illumination bag to a final 300 g by mass.
8-MOP was added to a final concentration of 0.9 M followed
by illumination in aMacogenic G2 UVA (peak wavelength, 365
nm) illumination device (Macopharma), which delivered 2 or
2.5 J/cm2 depending on the suspension’s hematocrit of2% or
2%, respectively, for 10–15 min. Before and after illumina-
tion, 2-ml samples were taken aseptically from the bag for this
study, and PBMCs were prepared followed by activation of
T-cells as described above. A total of three independent ECP
procedures were performed over a period of 2 months. Three
technical replicates per sample series were performed to
control for variation in SDS-PAGE Western blotting and
densitometry.
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